Picture3.jpg
Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
June 02, 2022 07:48 ET | Clearmind Medicine Inc.
No dedicated treatment currently available for cocaine addiction VANCOUVER, June 02, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the...
scilogo.jpg
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
May 27, 2022 09:15 ET | SciSparc Ltd
TEL AVIV, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
Picture3.jpg
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24, 2022 08:30 ET | Clearmind Medicine Inc.
Pre-clinical trial based on the proprietary combination demonstrates high safety profile in addition to a significant suppressive effect on alcohol consumption Vancouver, May 24, 2022 ...
scilogo.jpg
SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24, 2022 08:30 ET | SciSparc Ltd
Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption TEL AVIV, Israel, May 24, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd....
scilogo.jpg
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
May 10, 2022 08:30 ET | SciSparc Ltd
Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption TEL AVIV, Israel, May 10, 2022 (GLOBE NEWSWIRE)...
scilogo.jpg
Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain
March 30, 2022 08:30 ET | SciSparc Ltd
Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....